全球制药行业报告2011.pdfVIP

Pharma RD Annual Review 2011 1 ay is the time when Citeline Drug Intelligence’s Annual Review of trends in pharmaceutical RD is traditionally conducted. It is a useful opportunity to pause and reflect on how the industry is continu- M ing to evolve, and is also the time when we take the annual snapshot of our data which provides a new timepoint for our Trends data module in one of our database products, Pharmaprojects. In this article, we examine the data for 2011, look at how it has changed since 2010, and try to put the information into some sort of context. Some of the key points covered in this report include: • Growth of overall RD pipeline flat • Few novel new active substances launched in past year • 13% growth in drugs at Phase III status • Pfizer holds position as company with most drugs in development • Cancer takes 28% slice of RD pie • Poor year for newly-identified drug targets Overall Decline in TOTal number Of acTive Drugs The total number of Active drugs currently reported on the So should we be concerned at all about this apparent tapering database is almost unchanged for 2011, with the figure of off? In a year which has seen more RD job losses and 9,713 representing a small but insignificant decline (0.2%) faltering recovery in many of the world’s economies, it is from the 2010 number of 9,737. This would appear to con- probably a comforting sign that the number of drugs in firm a trend, the beginnings of which were seen last year, development has more-or-less held up. As we shall see of a plateauing off the longer-term trend of year-on-year when we come to dissect the RD landscape more closely, increases. Figure 1 includes the totals reported at this time there are some encouragi